Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANL NASDAQ:DSGN NASDAQ:ELDN NASDAQ:TVGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANLAdlai Nortye$1.79-0.6%$1.61$1.10▼$3.89$66.42M-0.9411,223 shs7,097 shsDSGNDesign Therapeutics$6.03+1.2%$4.79$2.60▼$7.77$339.41M1.61165,203 shs126,139 shsELDNEledon Pharmaceuticals$2.42-4.7%$3.01$2.38▼$5.54$152.10M-0.12642,976 shs677,478 shsTVGNTevogen Bio$0.87-1.6%$1.01$0.26▼$3.09$173.83M-0.78506,690 shs261,318 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANLAdlai Nortye+1.69%+2.27%+10.09%+6.82%-16.28%DSGNDesign Therapeutics-2.77%-2.45%+19.68%+55.21%+14.18%ELDNEledon Pharmaceuticals-1.93%-2.68%-4.51%-11.50%-0.78%TVGNTevogen Bio+1.28%+0.50%-8.19%-28.73%+101.34%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANLAdlai Nortye$1.79-0.6%$1.61$1.10▼$3.89$66.42M-0.9411,223 shs7,097 shsDSGNDesign Therapeutics$6.03+1.2%$4.79$2.60▼$7.77$339.41M1.61165,203 shs126,139 shsELDNEledon Pharmaceuticals$2.42-4.7%$3.01$2.38▼$5.54$152.10M-0.12642,976 shs677,478 shsTVGNTevogen Bio$0.87-1.6%$1.01$0.26▼$3.09$173.83M-0.78506,690 shs261,318 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANLAdlai Nortye+1.69%+2.27%+10.09%+6.82%-16.28%DSGNDesign Therapeutics-2.77%-2.45%+19.68%+55.21%+14.18%ELDNEledon Pharmaceuticals-1.93%-2.68%-4.51%-11.50%-0.78%TVGNTevogen Bio+1.28%+0.50%-8.19%-28.73%+101.34%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANLAdlai Nortye 2.00Hold$9.00402.79% UpsideDSGNDesign Therapeutics 0.00N/AN/AN/AELDNEledon Pharmaceuticals 2.75Moderate Buy$10.00313.22% UpsideTVGNTevogen Bio 3.00Buy$10.001,049.43% UpsideCurrent Analyst Ratings BreakdownLatest ANL, TVGN, ELDN, and DSGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/4/2025TVGNTevogen BioD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.009/2/2025ELDNEledon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.008/18/2025ELDNEledon PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/18/2025TVGNTevogen BioD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.008/4/2025TVGNTevogen BioD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.007/25/2025ELDNEledon PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.006/18/2025ELDNEledon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy$9.006/18/2025TVGNTevogen BioD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.00(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANLAdlai Nortye$5M13.21N/AN/A$0.69 per share2.59DSGNDesign TherapeuticsN/AN/AN/AN/A$4.28 per shareN/AELDNEledon PharmaceuticalsN/AN/AN/AN/A$1.05 per shareN/ATVGNTevogen BioN/AN/AN/AN/A($0.09) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANLAdlai Nortye-$51.87MN/A0.00N/AN/AN/AN/AN/AN/ADSGNDesign Therapeutics-$49.59M-$1.12N/AN/AN/AN/A-27.15%-26.07%11/6/2025 (Estimated)ELDNEledon Pharmaceuticals-$36.18M-$1.17N/AN/AN/AN/A-92.51%-38.31%11/11/2025 (Estimated)TVGNTevogen Bio-$13.73MN/A0.00∞N/AN/AN/A-775.49%11/10/2025 (Estimated)Latest ANL, TVGN, ELDN, and DSGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/19/2025N/ATVGNTevogen Bio-$0.05-$0.03+$0.02-$0.03N/AN/A8/14/2025Q2 2025ELDNEledon Pharmaceuticals-$0.23-$0.13+$0.10-$0.13N/AN/A8/7/2025Q1 2025DSGNDesign Therapeutics-$0.32-$0.34-$0.02-$0.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANLAdlai NortyeN/AN/AN/AN/AN/ADSGNDesign TherapeuticsN/AN/AN/AN/AN/AELDNEledon PharmaceuticalsN/AN/AN/AN/AN/ATVGNTevogen BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANLAdlai Nortye0.021.411.41DSGNDesign TherapeuticsN/A25.1325.13ELDNEledon PharmaceuticalsN/A8.128.12TVGNTevogen BioN/A0.260.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANLAdlai Nortye35.21%DSGNDesign Therapeutics56.64%ELDNEledon Pharmaceuticals56.77%TVGNTevogen BioN/AInsider OwnershipCompanyInsider OwnershipANLAdlai NortyeN/ADSGNDesign Therapeutics23.50%ELDNEledon Pharmaceuticals12.30%TVGNTevogen Bio73.24%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANLAdlai Nortye12736.90 millionN/ANot OptionableDSGNDesign Therapeutics4056.95 million43.57 millionOptionableELDNEledon Pharmaceuticals1059.88 million52.52 millionOptionableTVGNTevogen Bio3196.71 million52.64 millionN/AANL, TVGN, ELDN, and DSGN HeadlinesRecent News About These CompaniesTevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in BostonSeptember 10 at 11:59 AM | globenewswire.comTevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B InfectionSeptember 9 at 3:15 PM | globenewswire.comTevogen Bio Inc: Tevogen Values TVGN-489 at $9-$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell Allogeneic T Cell PlatformSeptember 9 at 2:05 AM | finanznachrichten.deTevogen values TVGN-480 at $9B-$11B rNPVSeptember 9 at 2:05 AM | msn.comTevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell PlatformSeptember 8, 2025 | globenewswire.comTevogen Bio Holdings Inc. (NASDAQ:TVGN) Short Interest UpdateSeptember 8, 2025 | marketbeat.comTevogen Bio's (TVGN) "Buy" Rating Reiterated at D. Boral CapitalSeptember 7, 2025 | americanbankingnews.comTevogen Bio's (TVGN) "Buy" Rating Reaffirmed at D. Boral CapitalSeptember 6, 2025 | marketbeat.comTevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on ...September 4, 2025 | bakersfield.comBTevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and LymphomasSeptember 4, 2025 | globenewswire.comTevogen Bio Highlights Promising Clinical Results for TVGN 489 in Treating SARS-CoV-2 in Immunocompromised PatientsSeptember 3, 2025 | quiverquant.comQTevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2September 3, 2025 | globenewswire.comTevogen Bio Inc: Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation DisclosureAugust 28, 2025 | finanznachrichten.deTevogen Bio Holdings Inc. Highlights Internally Developed Assets Reflecting Long-Term ValueAugust 27, 2025 | quiverquant.comQTevogen Bio Highlights Proprietary Assets and Upcoming Valuation DisclosureAugust 27, 2025 | globenewswire.comTevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company’s Mission of Health EquityAugust 26, 2025 | markets.businessinsider.comTevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company's Mission of Health EquityAugust 26, 2025 | globenewswire.comTevogen Bio Holdings Inc. Reports 24% Increase in Institutional Ownership in Q2 2025August 25, 2025 | quiverquant.comQTevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained PositionsAugust 25, 2025 | globenewswire.comTevogen Recognized in BINJE’s BEST Health Care 2025 for Advancing Health Equity and Sustainable BiopharmaAugust 22, 2025 | markets.businessinsider.comTevogen Bio Holdings Inc. Recognized in BINJE's BEST Health Care 2025 for Commitment to Health Equity and InnovationAugust 22, 2025 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeANL, TVGN, ELDN, and DSGN Company DescriptionsAdlai Nortye NASDAQ:ANL$1.77 -0.03 (-1.61%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.Design Therapeutics NASDAQ:DSGN$6.03 +0.07 (+1.17%) Closing price 04:00 PM EasternExtended Trading$6.04 +0.01 (+0.17%) As of 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.Eledon Pharmaceuticals NASDAQ:ELDN$2.42 -0.12 (-4.72%) Closing price 04:00 PM EasternExtended Trading$2.50 +0.08 (+3.31%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.Tevogen Bio NASDAQ:TVGN$0.87 -0.01 (-1.55%) Closing price 04:00 PM EasternExtended Trading$0.87 0.00 (-0.34%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
